SCHEMBL25785686

SCHEMBL25785686

CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(NC(=O)OC(C)(C)C)cc3)nc2N1C1CCCC1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 18/20 0.67
PLK3 Q9H4B4 16/20 0.67
PLK2 Q9NYY3 15/20 0.67
BRD4 O60885 4/20 0.65
TAF1 P21675 1/20 0.65
PARP1 P09874 1/20 0.59
PRKD3 O94806 1/20 0.57
MAP4K4 O95819 1/20 0.57
PRKCG P05129 1/20 0.57
CLK2 P49760 1/20 0.57
RPS6KA3 P51812 1/20 0.57
NEK4 P51957 1/20 0.57
PTK2 Q05397 1/20 0.57
CAMK2G Q13555 1/20 0.57
CAMK2D Q13557 1/20 0.57
SRPK1 Q96SB4 1/20 0.57
PRKD2 Q9BZL6 1/20 0.57
CSNK1G1 Q9HCP0 1/20 0.57
CSNK1G3 Q9Y6M4 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27778420 0.87 PLK1 (0.59) PLK1PLK3PLK2BRD4TAF1
SCHEMBL27778422 0.87 PLK1 (0.59) PLK1PLK3PLK2BRD4TAF1
SCHEMBL376015 0.85 PLK1 (0.77) PLK1PLK3PLK2BRD4TAF1
SCHEMBL27757440 0.85 PLK1 (0.57) PLK1PLK3PLK2BRD4TAF1
SCHEMBL27757436 0.85 PLK1 (0.57) PLK1PLK3PLK2BRD4TAF1
SCHEMBL25785843 0.85 BRD4 (0.74) PLK1PLK3PLK2BRD4TAF1
SCHEMBL17507107 0.85 BRD4 (0.76) PLK1PLK3PLK2BRD4TAF1
SCHEMBL17507106 0.85 BRD4 (0.76) PLK1PLK3PLK2BRD4TAF1
SCHEMBL30110150 0.85 BRD4 (0.76) PLK1PLK3PLK2BRD4TAF1
SCHEMBL375836 0.84 PLK1 (0.56) PLK1PLK3PLK2BRD4TAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 PLK1 733/4885PLK3 961/4885PLK2 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.